A life sciences startup backed by one of the region’s most active investment groups will be looking to raise new funding this year as it continues to work through clinical trials for its lead product.
Alphyn Biologics, a clinical-stage dermatology company developing a new class of drugs for skin diseases, will pursue a Series B financing round in 2023. It did not give a target raise. The company, based in Cincinnati and Annapolis, Md., just announced in September an oversubscribed $3.3 million…
